Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 201,370 | -1,181 | -941 | -662 | -271 |
| Depreciation Amortization | N/A | N/A | -165 | -26 | N/A |
| Accounts payable and accrued liabilities | 125 | -148 | -96 | N/A | -126 |
| Other Working Capital | 226 | -64 | -94 | -261 | 37 |
| Other Operating Activity | -203,035 | -129 | 69 | -75 | 4 |
| Operating Cash Flow | $-1,314 | $-1,522 | $-1,227 | $-1,024 | $-356 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 3,000 | -12,588 | -12,656 | -8,811 | N/A |
| Other Investing Activity | 225,000 | 139 | 139 | 139 | 139 |
| Investing Cash Flow | $228,000 | $-12,449 | $-12,517 | $-8,672 | $139 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,485 | 521 | 388 | 388 | 179 |
| Financing Cash Flow | $1,485 | $521 | $388 | $388 | $179 |
| Beginning Cash Position | 5,989 | 19,439 | 19,439 | 19,439 | 19,439 |
| End Cash Position | 234,160 | 5,989 | 6,083 | 10,131 | 19,401 |
| Net Cash Flow | $228,171 | $-13,450 | $-13,356 | $-9,308 | $-38 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,314 | -1,522 | -1,227 | -1,024 | -356 |
| Free Cash Flow | -1,314 | -1,522 | -1,227 | -1,024 | -356 |